BACARDI-LIMITED
16.9.2022 16:05:40 CEST | Business Wire | Press release
Bacardi Limited, the largest privately held spirits company in the world, today announces moves within its global marketing leadership. John Burke, Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited, will retire after more than 28 years with the company at the end of 2022. During his tenure, he led many of the company’s leading brands, including most recently BACARDÍ® rum, BOMBAY SAPPHIRE® gin, MARTINI® vermouths and sparkling wines, and DEWAR’S® Blended Scotch whisky.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005301/en/
Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. (Photo: Business Wire)
“John is an incredibly strategic marketer who has helped us reinvigorate many brands and keep consumer at the heart of everything that we do. He played an important role in creating a disciplined marketing organization focused on building capabilities and driving brand equity over the years,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited. “Under his leadership, we have seen many magical moments for our brands. He leaves us having imprinted his mark in our story – and a legacy he can be very proud of.”
“I am incredibly grateful for the many opportunities I have been given in my lifetime at Bacardi. I have had the opportunity to work with and learn from some remarkable people, and I hope I have been able to help them in return. I have loved nurturing our brands to make them stronger and see them grow,” says John Burke. “I am very proud of what we have achieved together and wish Bacardi good fortune and continued success for the future.”
Following John’s retirement, Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. Since 2017, Ned has led BACARDÍ® rum, first in market execution in North America and later globally from Bermuda as SVP. In addition to his continued leadership of BACARDÍ rum, he will add MARTINI®, DEWAR’S®, WILLIAM LAWSON’S®, D’USSÉ® Cognac, among others. Ned’s ascension is the culmination of a 17-year-tenure at Bacardi that began as an Assistant Brand Manager. His career has spanned assignments at regional and global levels working on many company brands, including DEWAR’S®, GREY GOOSE®, BOMBAY SAPPHIRE®, OXLEY®, ST-GERMAIN®, D’USSÉ®, and others. Ned, who will relocate to London, will report to CEO Mahesh Madhavan and joins the Global Leadership Team (GLT).
“I am incredibly honored and humbled to assume the role of CMO at Bacardi,” says Ned Duggan. “I have spent my career at this company, learning from the best and I am thrilled to enter this next phase of my journey working to further develop and grow our renowned portfolio.”
Kathy Parker, President & CMO of GREY GOOSE® vodka and the tequila portfolio, which includes PATRÓN® and CAZADORES®, will add BOMBAY SAPPHIRE® gin to her remit following John’s retirement. Kathy is a member of the company’s Global Leadership Team and reports to CEO Mahesh Madhavan.
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005301/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom